MiR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ b-Catenin/BCL9 pathway

Cancer Research

Volumn 74, Issue 6, 2014, Pages 1801-1813

  Zhao, Jian Jun ^a   Lin, Jianhong ^a,b   Zhu, Di ^a   Wang, Xujun ^h   Brooks, Daniel ^f   Chen, Ming ^a   Chu, Zhang Bo ^a   Takada, Kohichi ^a   Ciccarelli, Bryan ^a   Admin, Samir ^c   Tao, Jianguo ^g   Tai, Yu Tzu ^a,b   Treon, Steven ^a   Pinkus, Geraldine ^d   Kuo, Winston Patrick ^e   Hideshima, Teru ^a,b   Bouxsein, Mary ^f   Munshi, Nikhil ^a,b   Anderson, Kenneth ^a,b   Carrasco, Ruben D ^a,d  

^a Department of Medical Oncology ^*  (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCL9 PROTEIN; BETA CATENIN; LUCIFERASE; MICRORNA 30 5P; ONCOPROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; BONE MARROW CELL; CANCER PROGNOSIS; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RNA INTERFERENCE; TUMOR BURDEN; WNT SIGNALING PATHWAY;

EID: 84896532358     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3311-T     Document Type: Article

References (46)

1. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, riskstratification, and management. Am J Hematol 2011;86:57-65.
2. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122:3456-63.
3. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
4. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002; 109:47-60. (Pubitemid 34327516)
5. Townsley FM, Cliffe A, Bienz M. Pygopus and legless target Armadillo/ b-catenin to the nucleus to enable its transcriptional co-Activator function. Nat Cell Biol 2004;6:626-33. (Pubitemid 38960920)
6. Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. Crystal structure of a b-catenin/BCL9/Tcf4 complex. Mol Cell 2006; 24:293-300.
7. DerksenPW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van OersMH, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 2004;101:6122-7. (Pubitemid 38520538)
8. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9: 313-25.
9. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 2009;69:7577-86.
10. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, et al. Targeted disruption of the BCL9/b-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 2012;4:148ra17.
11. Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 2003;22:1536-45. (Pubitemid 36390603)
12. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72.
13. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, et al. Aurora kinase A is a target of Wnt/b-catenin involved in multiple myeloma disease progression. Blood 2009;114:2699-708.
14. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998;91:1873-81. (Pubitemid 28185487)
15. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
16. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
17. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-81.
18. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11. (Pubitemid 351185806)
19. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, et al. Targeting the b-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 2007;104:7516-21. (Pubitemid 47185938)
20. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115:2630-9.
21. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor a and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283:31079-86.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are micro-RNA targets. Cell 2005;120:15-20. (Pubitemid 40094598)
23. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37: 495-500. (Pubitemid 40617277)
24. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-Associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56-65.
25. Zhou Y,Chen L,Barlogie B, StephensO, Wu X, Williams DR, et al. Highrisk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad SciUS A 2010;107:7904-9.
26. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98. (Pubitemid 47106630)
27. Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, et al. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 2011;25:145-52.
28. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
29. Baron R, Kneissel M.WNTsignaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013;19:179-92.
30. Tian E, Zhan F,Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349: 2483-94. (Pubitemid 38010074)
31. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
32. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of b-catenin and GSK3b. Br J Cancer 2003;89:1298-304. (Pubitemid 37363420)
33. Polakis P. Drugging Wnt signalling in cancer. EMBO J 2012;31: 2737-46.
34. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50. (Pubitemid 40558990)
35. Deka J, Wiedemann N, Anderle P, Murphy-Seiler F, Bultinck J, Eyckerman S, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res 2010;70:6619-28.
36. Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM. MicroRNA-30c-2 expressed in ovarian cancer cells suppresses growth factorinduced cellular proliferation and downregulates the oncogene BCL9.
37. Mol Cancer Res 2011;9:1732-45.
38. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;27:91-105. (Pubitemid 46991392)
39. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010;29:4194-204.
40. Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci U S A 2011;108:522-7.
41. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-Type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 2006;103:2746-51.
42. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N, et al. In vitro and in vivo anti-Tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55.
43. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013;19:2096-106.
44. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70.
45. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA. miRNAs and their potential for use against cancer and other diseases. Future Oncol 2007;3:521-37. (Pubitemid 47595862)
46. Gu J, Iyer VR. PI3K signaling and miRNA expression during the response of quiescent human fibroblasts to distinct proliferative stimuli. Genome Biol 2006;7:R42.